Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date February 28, 2020 · Filed March 03, 2020
Section 16 reporting ended · disclosed 2020-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,075 |
Ending reported balance
After 2020-02-28 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-02-28 · Exercise / conversion · Acquired 27,422 · Balance 140,744 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2020-02-28 · Tax withholding · Disposed 4,503 · Balance 136,241 F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Row 3 · 2020-02-28 · Tax withholding · Disposed 14,166 · Balance 122,075 F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $27.37 · Expires 2020-02-28 | Direct | 0 |
Reported balance
After 2020-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-28 · Exercise / conversion · Disposed 27,422 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 2,686 |
Reported balance
Holding disclosure · report date 2020-02-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,686 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2003 Filed Jul 2, 2003 15:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 59 | $34.15 Strike: $0.00 | $2,014.85 |
DisclosureSEC source: 0000078003-03-000125 · can374.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,704 Underlying: Common Stock · 59 shares Expires 1988-08-08 F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| June 13, 2003 Filed Jun 16, 2003 19:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 71 | $33.08 Strike: $0.00 | $2,348.68 |
DisclosureSEC source: 0000078003-03-000078 · can353.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,645 Underlying: Common Stock · 71 shares Expires 1988-08-08 F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| May 30, 2003 Filed Jun 2, 2003 17:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 64 | $31.02 Strike: $0.00 | $1,985.28 |
DisclosureSEC source: 0000078003-03-000066 · can344.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,574 Underlying: Common Stock · 64 shares Expires 1988-08-08 F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
| May 15, 2003 Filed May 16, 2003 16:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhamtom Stock Units SSP · Derivative | 75 | $33.53 Strike: $0.00 | $2,514.75 |
DisclosureSEC source: 0000078003-03-000055 · can340.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,510 Underlying: Common Stock · 75 shares Expires 1988-08-08 F1 · derivative.exercise_price: These units converto to common stock on a one-for-one basis. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.